HHS Announces Cost Savings for 64 Prescription Drugs Thanks to the Medicare Rebate Program Established by the Biden-Harris Administration’s Lower Cost Prescription Drug Law
There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.